
Keywords: CAD; coronary artery disease; DAPT; dual anti-platelet therapy; DES; drug eluting stent; DM; diabetes mellitus; L-DAPT; long dual anti-platelet therapy; MI; myocardial infarction; NACE; net adverse cardiovascular event; PCI; percutaneous coronary interven